Hormonal
Novel GLP-1 receptor agonists (e.g., NLY01, tirzepatide) are being developed to enhance central nervous system penetration and efficacy, with some showing specific benefits in younger patient subgroups.
Newer GLP-1 drugs like NLY01 and tirzepatide are being designed to work better in the brain. Early results suggest they might help younger patients more than older ones. If you are interested in these treatments, ask your doctor about the latest clinical trials and whether a newer agent might be suitable for your specific condition and age.
Newer agents, such as NLY01 and tirzepatide, are under development to enhance central nervous system penetration and efficacy... Subgroup analysis suggested some benefit in younger patients, but larger, targeted studies are needed.
Why this rating
Based on preclinical data and early-phase clinical trials (Phase II), with mixed results in broader populations.
Source
From metabolism to mind: The expanding role of the GLP-1 receptor in neurotherapeutics
Akash Roy et al. · Neurotherapeutics · 2025
DOI 10.1016/j.neurot.2025.e00712
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →